NLS-133
Phase 2Small molecule
NLS-133 is one of 11 small molecule programs targeting TIA. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in TIA
#DrugCompanyPhaseTrials
1Taxotere
AAvyxa
Phase 3
Venclexta
AbbViePhase 2
Gazyva
RochePhase 2
Calquence
AstraZenecaPhase 2
Sequential
PPeking Union Medical College Hospital
Phase 3
Tegafur-Gimeracil-Oteracil
NNational Taiwan University Hospital
Phase 3
BAY 987519
BayerPreclinical
NLS-133
NNext Life Sciences
Phase 2
Apelin
UUniversity of Edinburgh
Preclinical
Standard SPF 4 Sunscreen
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NLS-133. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNext Life Sciences